Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

× No keyword cloud information.

7 in total

Review 1. Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors: Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal: Drug Resist Updat Date: 2010-11-03 Impact factor: 18.500

2. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

Authors: Alfonso De Stefano; Chiara Carlomagno
Journal: World J Gastroenterol Date: 2014-08-07 Impact factor: 5.742

Review 3. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

Authors: Cristiana Lo Nigro; Vincenzo Ricci; Daniela Vivenza; Cristina Granetto; Teresa Fabozzi; Emanuela Miraglio; Marco C Merlano
Journal: World J Gastroenterol Date: 2016-08-14 Impact factor: 5.742

Review 4. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Authors: Hui-Yan Luo; Rui-Hua Xu
Journal: World J Gastroenterol Date: 2014-04-14 Impact factor: 5.742

5. miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor.

Authors: Qin Qin; Furong Wei; Jianbo Zhang; Xingwu Wang; Baosheng Li
Journal: J Cell Mol Med Date: 2016-05-31 Impact factor: 5.310

6. Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.

Authors: Ye Jiang; Jing Zhang; Juanjuan Huang; Bo Xu; Ning Li; Lei Cao; Mingdong Zhao
Journal: BMC Pulm Med Date: 2018-11-20 Impact factor: 3.317

7. Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib.

Authors: You-Cai Zhu; Bing Wan; Li-Xin Wu; Xing-Liang Li; Wen-Xian Wang; Chun-Wei Xu; Wu Zhuang; Jian-Guo Wei; Kai-Qi Du
Journal: Transl Cancer Res Date: 2019-08 Impact factor: 1.241

7 in total